The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens
Abstract
BACKGROUND: Orforglipron, an oral non-peptide GLP-1 receptor agonist, is being evaluated for type 2 diabetes mellitus (T2DM) and obesity. A quantitative synthesis of efficacy and safety across doses and phenotypes is needed. OBJECTIVE: To assess the efficacy and safety of orforglipron versus placebo in adults with T2DM and/or obesity, including prespecified subgroup analyses by dose and metabolic phenotype, along with certainty evaluation using GRADE and trial sequential analysis (TSA). METHODS: Following PRISMA 2020, randomized controlled trials comparing orforglipron with placebo were combined using random-effects meta-analysis to determine mean differences (MD) or risk ratios (RR) with 95% confidence intervals. Heterogeneity (I²), influence (leave-one-out analysis), dose groups (3, 6, 24, 36 mg), and phenotype subgroups (obese/non-diabetic vs. non-obese/diabetic) were analyzed; TSA evaluated the required information size and monitoring boundaries. RESULTS: Five trials (n = 2,672; orforglipron 1,413; placebo 1,259) were included. Orforglipron reduced HbA1c (primary MD − 1.07%, 95% CI − 2.00 to − 0.13; I²=100%; sensitivity MD − 1.45%, 95% CI − 1.49 to − 1.41; I²=0%), body weight (primary MD − 5.25 kg, 95% CI − 6.72 to − 3.77; I²=96%; sensitivity MD − 4.21 kg, 95% CI − 4.40 to − 4.02; I²=0%), BMI (MD − 1.99 kg/m², 95% CI − 2.97 to − 1.01; I²=97%), and systolic blood pressure (primary MD − 3.90 mmHg, 95% CI − 6.44 to − 1.35; I²=91%; sensitivity MD − 2.56 mmHg, 95% CI − 4.64 to…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Orforglipron (LY3502970) is a novel, orally available, nonpeptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) designed to replicate the efficacy of injectable GLP-1 RAs for glycemic control and weight reduction while improving convenience and adherence.”
From Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes (2026) · cites this paper as [31]
Citations
Cites
The PRISMA 2020 statement: An updated guideline for reporting systematic reviews
Page, M. J., McKenzie, J. E., Bossuyt, P. M., Boutron, I., Hoffmann, T. C., Mulrow, C. D., Shamseer, L., Tetzlaff, J. M., Akl, E. A., Brennan, S. E., et al. (2021) · BMJ · doi:10.1136/bmj.n71 · Cited by 108,283
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
2. Classification and Diagnosis of Diabetes:Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Gaglia, J. L., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s002 · Cited by 2,433
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis
Wetterslev, J., Thorlund, K., Brok, J., & Gluud, C. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.03.013 · Cited by 1,881
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Trial Sequential Analysis in systematic reviews with meta-analysis
Wetterslev, J., Jakobsen, J. C., & Gluud, C. (2017) · BMC Medical Research Methodology · doi:10.1186/s12874-017-0315-7 · Cited by 1,189
Research works printed but not linked: 5
- Bækdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Søndergaard FL, Borregaard J (2021) Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Ther Res Treat Educ Diabetes Relat Disord 12(7):1915–1927
- Fredrick TW, Camilleri M, Acosta A (2025) Pharmacotherapy for obesity: recent updates. Clin Pharmacol Adv Appl 17:305–327
- Pantea I, Repanovici A, Andreescu O (2024) The influence of GLP1 on body weight and glycemic management in patients with diabetes-A scientometric investigation and visualization study. Med Kaunas Lith 60(11):1761
- Repanovici A, Rogozea LM, Pantea I (2024) GLP-1 and body weight: a scientometric analysis about how to select the best articles containing pharmacological treatment methods. Am J Ther 31(6):e659–e668
- Sedrak P, Verma R, Verma M, Connelly KA (2025) Evolving role of double and triple therapy with GLP-1 receptor agonists in obesity and cardiovascular disease. Can J Cardiol 41(9):1809–1822
Cited by
Kansakar, U., Jankauskas, S. S., Pande, S., Mone, P., Varzideh, F., & Santulli, G. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031409 · Cited by 22
Imran, R., Imran, M., & Roshan, M. (2026) · Acta Diabetologica · doi:10.1007/s00592-026-02696-3
Khattak, M., Abbas, S. A., Zaryab, U., Bibi, H., Siddiqui, S. A., Khan, B. W., Zeeshan, N., Khan, M. F., Amjad, M. M., Khan, N. A., et al. (2026) · International Journal of Obesity · doi:10.1038/s41366-026-02221-0
Self-citation
Metadata
- Authors
- Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., Mohmand, M. S., Bacha, Z., Khan, B. W., Jamal, T., Khalid, A. A., Khan, M. I., & Zulkaif, M.
- Affiliations
- Khyber Medical College (PK)
- Jinnah Sindh Medical University (PK)
- Allama Iqbal Medical College (PK)
- Bacha Khan Medical College (PK)
- Dow University of Health Sciences (PK)
- National Institute of Health (PK)
- Medical University of Sofia (BG)
- Corresponding author
- Khan, Suleman
- ORCID
- Venue
- Acta Diabetologica
- Published
- 2026-01-07
- Volume
- 63
- Issue
- 4
- Pages
- 711-725
- ISSN
- 0940-5429 (ISSN-L)
- 1432-5233
- OpenAlex
- W7119076038
- Cited by
- 3
- References
- 28
- Citations by year
- 2026: 3
- FWCI
- 3.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Acta Diabetologica (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- orforglipron, GLP-1 receptor agonists, type 2 diabetes, obesity, HbA1c, weight loss, systolic blood pressure, dose-response relationship, subgroup analysis, trial sequential analysis, GRADE certainty, drug safety, adverse events, glycemic control, blood pressure reduction, required information size
- MeSH terms
- Blood Glucose, Diabetes Mellitus, Type 2, Dose-Response Relationship, Drug, Humans, Hypoglycemic Agents, Obesity, Oxadiazoles, Randomized Controlled Trials as Topic, Treatment Outcome, Fluorine Compounds
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens. https://app.cochat.ai/papers/10.1007/s00592-025-02635-8
- The paper
- Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., Mohmand, M. S., Bacha, Z., Khan, B. W., Jamal, T., Khalid, A. A., Khan, M. I., & Zulkaif, M. (2026). Efficacy and safety of orforglipron in type 2 diabetes mellitus and obesity: a GRADE-assessed meta-analysis and trial sequential analysis with subgroup evaluations by diabetic status, obesity status, and dose regimens. Acta Diabetologica. https://doi.org/10.1007/s00592-025-02635-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.